Second-Line Treatment in Patients (pts) with Advanced Extra-Pulmonary Poorly Differentiated Neuroendocrine Carcinoma (EP-PD-NEC): A Systematic Review and Meta-Analysis

被引：0
|
作者：
McNamara, M. G. [1 ]
Frizziero, M. [2 ]
Jacobs, T. [2 ]
Lamarca, A. [2 ]
Hubner, R. [2 ]
Valle, J. W. [1 ]
Amir, E. [3 ]
机构：
[1] Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
NEUROENDOCRINOLOGY | 2019年 / 108卷
关键词：
second-line therapy; neuroendocrine carcinoma; response rate; survival; extra-pulmonary;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
J12
引用
下载
收藏
页码：188 / 188
页数：1
相关论文
共 50 条
  • [1] Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis
    McNamara, Mairead G.
    Frizziero, Melissa
    Jacobs, Timothy
    Lamarca, Angela
    Hubner, Richard A.
    Valle, Juan W.
    Amir, Eitan
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [2] Impact of Small Cell (SC) versus (vs.) Non-Small Cell (nSC) Morphology on Outcomes of Patients (pts) with Extra-Pulmonary, Poorly Differentiated Neuroendocrine Carcinoma (EP-PD-NEC)
    Zaninotto, E.
    Frizziero, M.
    Durand, A.
    Taboada, R. G.
    Luchini, C.
    Oliveira, P.
    Hervieu, V
    Claro, L. C. L.
    Cingarlini, S.
    Walter, T.
    Riechelmann, R.
    McNamara, M.
    NEUROENDOCRINOLOGY, 2020, 110 : 244 - 244
  • [3] Carboplatin-Etoposide Chemotherapy (CB-ET) for Patients Diagnosed with Advanced Extra-Pulmonary (EP) Poorly Differentiated (PD) Neuroendocrine Carcinoma (NEC): Findings from a European Neuroendocrine Tumor Society Centre of Excellence
    Frizziero, M.
    Lamarca, A.
    Kordatou, Z.
    Barriuso, J.
    Nuttall, C.
    McNamara, M. G.
    Hubner, R.
    Mansoor, W.
    Manoharan, P.
    Valle, J.
    NEUROENDOCRINOLOGY, 2018, 106 : 77 - 77
  • [4] NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).
    McNamara, Mairead Geraldine
    Swain, Jayne
    Craig, Zoe
    Sharma, Rohini
    Faluyi, Olusola Olusesan
    Wadsley, Jonathan
    Morgan, Carys
    Wall, Lucy R.
    Chau, Ian
    Reed, Nick
    Sarker, Debashis
    Margetts, Jane
    Krell, Daniel
    Cave, Judith
    Sharmila, Sothi
    Anthoney, Alan
    Patel, Alkesh
    Lamarca, Angela
    Hubner, Richard A.
    Valle, Juan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] NET-02: A multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).
    McNamara, Mairead Geraldine
    Swain, Jayne
    Craig, Zoe
    Wadsley, Jonathan
    Reed, Nicholas
    Faluyi, Olusola Olusesan
    Lamarca, Angela
    Hubner, Richard
    Mansoor, Wasat
    Sarker, Debashis
    Howard, Helen C.
    Cairns, David A.
    Meyer, Tim
    Valle, Juan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Carboplatin (CB) combined with oral or intravenous (IV) etoposide (ET) for advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC): Real-world findings from two European neuroendocrine tumour society centres of excellence
    Frizziero, M.
    Spada, F.
    Lamarca, A.
    Kordatou, Z.
    Barriuso, J.
    Nuttall, C.
    McNamara, M. G.
    Hubner, R.
    Mansoor, W.
    Manoharan, P.
    Fazio, N.
    Valle, J. W.
    ANNALS OF ONCOLOGY, 2018, 29 : 472 - 472
  • [7] Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis
    Solimando, Antonio Giovanni
    Susca, Nicola
    Argentiero, Antonella
    Brunetti, Oronzo
    Leone, Patrizia
    De Re, Valli
    Fasano, Rossella
    Krebs, Markus
    Petracci, Elisabetta
    Azzali, Irene
    Nanni, Oriana
    Silvestris, Nicola
    Vacca, Angelo
    Racanelli, Vito
    CLINICAL AND EXPERIMENTAL MEDICINE, 2022, 22 (01) : 65 - 74
  • [8] Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis
    Larkin, James
    Paine, Abby
    Tumur, Indra
    Cappelleri, Joseph C.
    Healey, Paul J., Sr.
    Foley, Grace
    Mitchell, Stephen
    Kroes, Michel
    Chen, Connie
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (01) : 27 - 39
  • [9] Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis
    Antonio Giovanni Solimando
    Nicola Susca
    Antonella Argentiero
    Oronzo Brunetti
    Patrizia Leone
    Valli De Re
    Rossella Fasano
    Markus Krebs
    Elisabetta Petracci
    Irene Azzali
    Oriana Nanni
    Nicola Silvestris
    Angelo Vacca
    Vito Racanelli
    Clinical and Experimental Medicine, 2022, 22 : 65 - 74
  • [10] Health-related quality of life (HRQoL) in patients (pts) with progressive, poorly differentiated, extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) enrolled in NET-02: A phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy
    Craig, Zoe
    Swain, Jayne
    Sharma, Rohini
    Faluyi, Olusola Olusesan
    Wadsley, Jonathan
    Morgan, Carys
    Wall, Lucy R.
    Chau, Ian
    Reed, Nicholas Simon
    Sarker, Debashis
    Margetts, Jane
    Krell, Daniel
    Cave, Judith
    Sharmila, Sothi
    Anthoney, Alan
    Patel, Alkesh
    Lamarca, Angela
    Hubner, Richard A.
    Valle, Juan W.
    McNamara, Mairead Geraldine
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 293 - 293
12345